Immunic is developing a pipeline of oral therapies for chronic inflammatory and autoimmune diseases
Immunic is developing a pipeline of oral therapies for chronic inflamm…
Jun 21, 2023
proactiveinvestors.com
Immunic CEO on strong Q2 progress with vidofludimus calcium trials for MS
Immunic CEO on strong Q2 progress with vidofludimus calciu…
8 months ago
proactiveinvestors.com
Immunic reveals MS drug trial success
Immunic reveals MS drug trial success
9 months ago
proactiveinvestors.com
Immunic secures $400M to support late-stage MS trials - ICYMI
Immunic secures $400M to support late-stage MS trials - ICYMI
1 month ago
proactiveinvestors.com
Immunic CEO discusses MS focus, upcoming Phase 3 trial readouts - ICYMI
Immunic CEO discusses MS focus, upcoming Phase 3 trial readouts - …
5 months ago
proactiveinvestors.com
Immunic CMO on CALLIPER MS trial results at ECTRIMS
Immunic CMO on CALLIPER MS trial results at ECTRIMS
6 months ago
proactiveinvestors.com
Immunic advances drug targeting progressive multiple sclerosis during 3Q
Immunic advances drug targeting progressive multiple sclerosis dur…
Nov 14, 2023
proactiveinvestors.co.uk
Immunic showcases Phase 2 data on vidofludimus calcium at ACTRI…
2 months ago
proactiveinvestors.com
Immunic Therapeutics reaches major milestone with completion o…
10 months ago
proactiveinvestors.com
Immunic Theraputics
8 months ago
nasdaq.com
Immunic CEO on Q3 highlights, ECTRIMS 2025 and upcoming mile…
5 months ago
proactiveinvestors.com
Immunic highlights MS treatment progression at BIO International C…
9 months ago
proactiveinvestors.com
Immunic drug targeting post-COVID syndrome in Phase 2 trial - ICYMI
Sep 7, 2024
proactiveinvestors.com
Immunic COO Jason Tardio discusses key 2024 highlights, 20…
Jan 7, 2025
proactiveinvestors.com
Immunic says first patient enrolled in investigator-sponsored post-C…
Sep 5, 2024
proactiveinvestors.com
Immunic CSO discusses breaking the IBD stigma to mark Crohn's an…
Dec 2, 2024
proactiveinvestors.com
Immunic reports successful 2023 and prepares for key 2025 milesto…
Feb 22, 2024
proactiveinvestors.com
Immunic CEO on key 2025 highlights and 2026 milestones
3 months ago
proactiveinvestors.com
Immunic, Inc. Prioritizes Completion of the Ongoing Phase 3 Ensure Cli…
1 month ago
marketscreener.com
Immunic's IMU-856 shows promise as Celiac Disease Awareness Mon…
10 months ago
proactiveinvestors.com
Immunic Therapeutics taking a "unique approach" in biopharma
Feb 7, 2023
proactiveinvestors.com
Immunic CMO on Celiac Disease Awareness Month, potential of IM…
11 months ago
proactiveinvestors.com
Immunic Aktie (IMUX) | Aktienkurs » US4525EP1011 | wallstreetONLINE
Apr 15, 2019
wallstreet-online.de
Immunic's IMU-856 shows potential in gastrointestinal health trials - IC…
Nov 16, 2024
proactiveinvestors.co.uk
Immunic eyes Phase 3 after MS disability gains in Phase 2 CALLIP…
11 months ago
proactiveinvestors.com
Immunic reports first patient enrolled in investigator-sponsore…
Sep 4, 2024
proactiveinvestors.com
Immunic CEO on $400m financing, phase 3 MS plans
1 month ago
proactiveinvestors.com
Immunic Therapeutics shares IMU-856 mode of action and target for …
Jun 26, 2023
proactiveinvestors.com
Immunic announces oversubscribed private placement of up to USD 40…
1 month ago
marketscreener.com
World Brain Day: Immunic targets MS with new therapy
8 months ago
proactiveinvestors.com
See more videos
Static thumbnail place holder